A proposed collaboration with CBmed Ltd., Austria
Have compounds to test?
We can help you prioritize the right ones
Using patient-derived models and functional screening data to support
confident early-stage decisions
What We Deliver
Patient Sample Access
Access to heterogeneous, patient-
derived brain cancer samples across clinically relevant glioma subtypes.
Advanced Tumor Models
Advanced 3D spheroid models that better reflect tumor biology and heterogeneity.
High-throughput Compound Screening Platform
State-of-the-art laboratory automation with fully integrated devices.
Analytical Approach
Customized assay design enabling side-by-side compound comparison under standardized, clinically meaningful conditions, supported by integrated clinical data.
Project Output
Decision-ready comparative data package to support candidate prioritization and follow-up study design.
Special Offer
We offer an initial test phase under a special offer framework, as a low-risk entry point for your team to assess our platform performance, scientific quality, and collaborative execution in a real project setting.
This entry phase is designed to generate early prioritization insights while establishing the basis for broader strategic collaboration.
In this introductory phase, we will:
- Screen a small selected compound set across three patient-derived tumor cell lines
- Demonstrate the quality, relevance, and reproducibility of our screening approach
- Build confidence in our team, project delivery, and reporting standard
Proposed Timeline
NO COST Initial test phase (Weeks 1-6)
3 selected compounds on 3 patient-derived cell lines
Data Review & Assessment
Review of the initial test phase based on detailed report
Decision Point
Go/ No-go decision
Project Alignment
Collaborative finalization of project scope and workplan
Project Initiation
Project initiation
Milestone-Based Execution
Transparent milestone-based project execution